Priority Research Papers:
Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model
Metrics: PDF 1733 views | HTML 17336 views | ?
Gillian Borland1,*, Anna Kilbey1,*, Jodie Hay1, Kathryn Gilroy1, Anne Terry1, Nancy Mackay1, Margaret Bell2, Alma McDonald1, Ken Mills3, Ewan Cameron2 and James C. Neil1
1 Molecular Oncology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
2 School of Veterinary Medicine, University of Glasgow, Glasgow, UK
3 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK
* Joint first authors
James C. Neil, email:
Ewan Cameron, email:
Keywords: Runx1, lymphoma, myc, oncogene addiction
Received: February 19, 2016 Accepted: March 28, 2016 Published: April 02, 2016
The Runx genes function as dominant oncogenes that collaborate potently with Myc or loss of p53 to induce lymphoma when over-expressed. Here we examined the requirement for basal Runx1 activity for tumor maintenance in the Eµ-Myc model of Burkitt’s lymphoma. While normal Runx1fl/fl lymphoid cells permit mono-allelic deletion, primary Eµ-Myc lymphomas showed selection for retention of both alleles and attempts to enforce deletion in vivo led to compensatory expansion of p53null blasts retaining Runx1. Surprisingly, Runx1 could be excised completely from established Eµ-Myc lymphoma cell lines in vitro without obvious effects on cell phenotype. Established lines lacked functional p53, and were sensitive to death induced by introduction of a temperature-sensitive p53 (Val135) allele. Transcriptome analysis of Runx1-deleted cells revealed a gene signature associated with lymphoid proliferation, survival and differentiation, and included strong de-repression of recombination-activating (Rag) genes, an observation that was mirrored in a panel of human acute leukemias where RUNX1 and RAG1,2 mRNA expression were negatively correlated. Notably, despite their continued growth and tumorigenic potential, Runx1null lymphoma cells displayed impaired proliferation and markedly increased sensitivity to DNA damage and dexamethasone-induced apoptosis, validating Runx1 function as a potential therapeutic target in Myc-driven lymphomas regardless of their p53 status.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.